Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Stroup

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Biological Psychiatry|June 26, 2007
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophreniaDaniel B Campbell, Philip J Ebert, Tara Skelly, et al.
Schizophrenia Bulletin|August 12, 2003
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trialMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Statistics in Biopharmaceutical Research|April 30, 2019
Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia StudySonia M Davis, T Scott Stroup, Gary G Koch, et al.
Frontiers in Genetics|November 1, 2011
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study)Hemant K Tiwari, Amit Patki, Jeffrey Lieberman, et al.
The American Journal of Psychiatry|May 4, 2011
Effectiveness of switching from antipsychotic polypharmacy to monotherapySusan M Essock, Nina R Schooler, T Scott Stroup, et al.
The American Journal of Psychiatry|March 4, 2006
Barriers to employment for people with schizophreniaRobert Rosenheck, Douglas Leslie, Richard Keefe, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 21, 2008
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognitionJames J Crowley, Richard S E Keefe, Diana O Perkins, et al.
Psychiatric Services (Washington, D.C.)|April 3, 2018
Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United StatesT Scott Stroup, Tobias Gerhard, Stephen Crystal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 18, 2003
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazineJeffrey A Lieberman, Michael Phillips, Hongbin Gu, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 2, 2005
Measuring outcome priorities and preferences in people with schizophreniaRobert Rosenheck, Scott Stroup, Richard S E Keefe, et al.
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Biological Psychiatry|June 26, 2007
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophreniaDaniel B Campbell, Philip J Ebert, Tara Skelly, et al.
Schizophrenia Bulletin|August 12, 2003
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trialMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Statistics in Biopharmaceutical Research|April 30, 2019
Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia StudySonia M Davis, T Scott Stroup, Gary G Koch, et al.
Frontiers in Genetics|November 1, 2011
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study)Hemant K Tiwari, Amit Patki, Jeffrey Lieberman, et al.
The American Journal of Psychiatry|May 4, 2011
Effectiveness of switching from antipsychotic polypharmacy to monotherapySusan M Essock, Nina R Schooler, T Scott Stroup, et al.
The American Journal of Psychiatry|March 4, 2006
Barriers to employment for people with schizophreniaRobert Rosenheck, Douglas Leslie, Richard Keefe, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 21, 2008
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognitionJames J Crowley, Richard S E Keefe, Diana O Perkins, et al.
Psychiatric Services (Washington, D.C.)|April 3, 2018
Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United StatesT Scott Stroup, Tobias Gerhard, Stephen Crystal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 18, 2003
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazineJeffrey A Lieberman, Michael Phillips, Hongbin Gu, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 2, 2005
Measuring outcome priorities and preferences in people with schizophreniaRobert Rosenheck, Scott Stroup, Richard S E Keefe, et al.
Pageof 17